Novartis Gene Therapy Helps Children With Rare Muscle Disorder in Study

Reuters) – Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow. Novartis was testing the therapy, onasemnogene abeparvovec or OAV101 IT, in a late-stage trial of patients between the ages of 2 and less …
Read More